

Highlights

- Unrivalled Library Complexity - powered by ATOM-Seq® capture technology
- Developed for liquid biopsy samples
- Enhanced Error Correction - Error suppression protocol and unique molecular identifiers (UMI)
- Rapid Protocol With High Sample Retention – Minimal bead purification and hands on time

Our XCeloSeq® Pan Cancer cfDNA Kit employs our patented ATOM-Seq technology (Adaptor Template Oligo-Mediated Sequencing), which uses a simple and elegant chemistry to capture DNA, using sample DNA molecules as primers themselves, where their 3' ends are extended by a polymerase.

ATOM-Seq adds Unique Molecular Identifiers (UMIs) and universal adapter sequences directly to available 3' ends of every original sample molecule meaning that all original fragments can be captured. A universal primer is then used for rounds of linear amplification, allowing for the sequencing of both sense- and antisense-strands when the linear product is divided between two reactions thereby further improving error correction.

This unique approach is ligation free and is set apart from conventional PCR-based approaches by requiring only a single target-specific primer for enrichment. This offers numerous advantages that make ATOM-Seq particularly well suited to challenging clinical material such as cell-free DNA (cfDNA) from liquid biopsies or FFPE-preserved DNA.

The approach employed by ATOM-Seq along with unique protocol enhancements for sensitivity, specificity, and error correction allows for the highest sample retention and capture efficiency with no compromises on sensitivity and performance.

Specifications

Up to 50 ng
Input Quantity*

17 million
Recommended
Reads Per
Sample***

1147
Targeting
Primers**

1.5 Hours
Hands-On
Time


100
Gene
Targets

<6 hours
Total Protocol
Time

*Higher quantities within the range will improve maximum sensitivity, recommended maximum is 50 ng. Enzymatically fragmented FFPE is also supported as an alternative starting material, when 50 ng should be used.

**Targeting primers are split between the sense and antisense DNA strands.

***Suggested read number for cfDNA samples. Reads should be divided equally between Pool 1 and Pool 2 Libraries. Read numbers can be optimised by users for different uses. For example, for FFPE libraries fewer reads may be sufficient. When using FFPE enzymatic digestion is required.



ATOM-Seq Workflow

Sample DNA is combined with the Adapter Template Oligo. The DNA molecules anneal to the 3' end of the ATO and a polymerase extends the original molecule, using the ATO sequence as a template to add a Unique Molecular Identifier (UMI) and a universal priming site to the end of the captured molecule.

Next Generation Sequencing



Summary

The Pan Cancer cfDNA Kit is powered by our ATOM-Seq chemistry and is for use with cell-free DNA extracted from liquid biopsy blood samples. This kit is designed to target selected hotspots across 100 of the most frequently mutated genes in cancers and allows for high sensitivity and specificity detection of mutations including SNPs, insertions, deletions.

When used in conjunction with XCeloSeq Unique Dual Indexing Sets, these allow for the enrichment of nucleic acids to generate high quality, high-complexity next-generation sequencing libraries suitable for use with Illumina® next-generation sequencing (NGS) instruments.

Ordering Information


Product	No. of Samples	Catalog No.
XCeloSeq® Pan Cancer cfDNA Kit	8	SEQ002

Learn more

For more information including the protocol please visit www.genefirst.com

Further Information

Dunwell TL, Dailey SC, et al. Adaptor Template Oligo-Mediated Sequencing (ATOM-Seq) is a new ultra-sensitive UMI-based NGS library preparation technology for use with cfDNA and cfRNA. Sci Rep. 2021 Feb 4;11(1):3138. doi: 10.1038/s41598-021-82737-9. PMID: 33542447; PMCID: PMC7862664.



XCeloSeq® Pan Cancer cfDNA Workflow

ABL1	BRCA1	CHEK2	ESR1	GNAQ	KEAP1	MSH2	NTRK3	RHOA	SMO
AKT1	BRCA2	CSF1R	EZH2	GNAS	KIT	MSH6	PDGFRA	RIT1	SRC
ALK	CASP8	CTNNB1	FBXW7	HNF1A	KLF5	MTOR	PIK3CA	RNF43	STK11
AMER1	CCND1	DDR2	FGFR1	HRAS	KRAS	MYC	PTCH1	ROS1	TCF7L2
APC	CCND2	DMD	FGFR2	IDH1	MAP2K1	NF1	PTEN	SETD2	TP53*
AR	CCND3	EGFR	FGFR3	IDH2	MAP2K2	NFE2L2	PTPN11	SF3B1	TSC1
ARAF	CDH1	EP300	FGFR4	JAK2	MET	NOTCH1	RAF1	SMAD2	TSC2
ARID1A	CDK4	ERBB2	FLT3	JAK3	MGA	NPM1	RB1	SMAD4	UA2F1
ATM	CDK6	ERBB3	GATA3	KDM6A	MLH1	NRAS	RBM10	SMARCA4	VHL
BRAF	CDKN2A	ERBB4	GNA11	KDR	MPL	NTRK1	RET	SMARCB1	ZFP36L2

XCeloSeq® Pan Cancer cfDNA Kit Assay Targets. Selected target regions are enriched for the above genes (*Whole Coding Region Coverage).

© 2023 GeneFirst limited or one of its subsidiaries. ATOM-Seq and XCeloSeq are trademarks of GeneFirst Limited or one of its subsidiaries. All rights reserved. GeneFirst Limited pursues a policy of continuing improvement in design, production, and performance of its products. The right is therefore reserved to vary at any time and without notice.
Doc No: LIT0759v5.0

GeneFirst Limited • +44(0) 1865 407400 • www.genefirst.com

For Research Use Only. Not for use in diagnostic procedures



QR code to Website